MAO-A is one of the most clinically impactful genes on the MyHappyGenes® report and one of the most misunderstood. Patients with MAO-A variants frequently arrive in functional medicine practices after years of failed antidepressant trials, mood instability that doesn’t respond to standard interventions, or behavioral patterns that have damaged relationships and careers. Understanding the biochemistry behind MAO-A is often the missing piece that finally makes sense of their clinical picture.
This post is the clinical companion to our consumer-facing overview of the MAO-A gene. It’s written for licensed and certified practitioners working with the MyHappyGenes® reports.
MAO-A Function: A Brief Refresher
MAO-A — Monoamine Oxidase A, codes for an enzyme that degrades serotonin, dopamine, norepinephrine, and epinephrine in the synaptic cleft and in the liver. It is the primary enzyme responsible for serotonin clearance, which distinguishes it mechanistically from COMT, which primarily handles dopamine and norepinephrine and adrenalin in the prefrontal cortex.
MAO-A requires riboflavin (B2) as its essential cofactor, a point with significant clinical implications covered below.
The most studied variant is rs6323, with high-activity and low-activity alleles producing distinct clinical presentations. Because MAO-A is located on the X chromosome, hemizygous males express the variant more uniformly than females, who can be heterozygous and show more variable phenotypic expression.
Clinical Presentation: Low MAO-A Activity
Low MAO-A activity means serotonin, dopamine, and norepinephrine clear more slowly, producing a clinical picture dominated by excess monoamine activity, particularly under stress or when dietary amines are high.
Mood and behavioral symptoms: Irritability, reactive aggression, low frustration tolerance, impulsivity, and emotional volatility. These patients often describe feeling like they go from zero to ten with very little warning. Under chronic stress the presentation can tip into prolonged anger, hostility, and in some cases, aggressive behavior that is genuinely distressing to the patient as well as those around them.
It’s worth noting that low MAO-A patients are frequently highly driven, achievement-oriented, and effective under pressure, the same neurotransmitter profile that makes them reactive also makes them forceful and decisive. The clinical goal is not to flatten this but to stabilize it.
Sleep disruption: Elevated serotonin and norepinephrine at night can significantly impair sleep onset and quality. These patients often report feeling wired at bedtime despite genuine fatigue. And many report early waking.
Dietary amine sensitivity: Because MAO-A is also responsible for breaking down dietary amines, tyramine, histamine, phenylethylamine, low MAO-A patients can react strongly to aged cheeses, fermented foods, red wine, cured meats, and chocolate. Headaches, flushing, palpitations, and mood shifts after these foods are common and frequently go unconnected to MAO-A status.
Serotonin syndrome risk: This is a critical safety consideration. Low MAO-A patients on SSRIs, SNRIs, or other serotonergic medications carry an elevated risk of serotonin syndrome, particularly if additional serotonergic supplement, 5-HTP, St. John’s Wort, SAMe are introduced without careful management. Always review current medications before initiating any serotonin-pathway support in these patients.
Clinical Presentation: High MAO-A Activity
High MAO-A activity clears monoamines rapidly, producing a very different clinical picture, one that can look superficially similar to low MAO-A but has a different biochemical root.
These patients tend toward low mood, emotional flatness, lack of motivation, and in some cases, a melancholic or depressive presentation. They may be highly sensitive to loss and rejection. Unlike low MAO-A patients who react intensely, high MAO-A patients often describe feeling disconnected or emotionally muted.
Because serotonin is being cleared so efficiently, standard SSRI approaches may produce limited benefit, the medication is attempting to increase serotonin availability in a system that’s already clearing it aggressively.
The Riboflavin Connection
MAO-A’s dependence on riboflavin (B2) as a cofactor is one of the most clinically useful pieces of MAO-A biochemistry and one of the least discussed.
When riboflavin status is inadequate, MAO-A enzyme function is impaired regardless of genotype. This means that in some patients presenting with apparent low MAO-A symptoms, the primary issue may be riboflavin deficiency rather than genetic variant expression. Assessing and correcting riboflavin status before building a more complex protocol is a simple and often effective first step.
Riboflavin is also a cofactor for MTHFR, which means patients with both MAO-A and MTHFR variants have a compounded need for adequate B2. This is worth building into protocols for patients carrying both variants, which is not uncommon.
Dietary Considerations
Beyond the amine sensitivity noted above, low MAO-A patients generally benefit from a lower tyramine diet during the initial stabilization phase. Key foods to reduce or temporarily eliminate include aged and fermented cheeses, cured and smoked meats, fermented beverages, soy sauce and miso, and overripe or dried fruits.
This dietary modification can produce noticeable mood stabilization relatively quickly in sensitive patients, sometimes within days and is a useful early clinical win while longer-term cofactor support takes effect.
Cofactor and Supplement Protocol
For low MAO-A activity:
Core support centers on riboflavin (B2) as the primary MAO-A cofactor, alongside broader methylation support, methylated B vitamins, magnesium, and zinc. Magnesium is particularly useful for its calming effect on the nervous system and its role in supporting neurotransmitter regulation broadly.
For mood stabilization, inositol has clinical evidence for reducing irritability and emotional reactivity and is generally well tolerated in low MAO-A patients. Theanine can support calm without sedation and is a useful adjunct for sleep onset issues.
Avoid or use with caution: 5-HTP, SAMe, and St. John’s Wort in low MAO-A patients without careful monitoring. Tryptophan supplementation should also be approached carefully given its role as the serotonin precursor.
In addition, turmeric and curcumin have been shown to be antagonists to MAO-A function and are contraindicated in the low activity variants.
For high MAO-A activity:
Supporting serotonin and dopamine production upstream is the primary clinical goal. Tryptophan and 5-HTP as serotonin precursors, alongside tyrosine for dopamine support, with appropriate cofactors, B6, zinc, and iron, for synthesis pathway function.
SAMe is generally better tolerated in high MAO-A patients than in low MAO-A patients and can be a useful tool for mood support in this group. Overmethylation can be particularly harmful in those with low MAO-A function.
Kinesiology Challenge Vials
For practitioners using applied kinesiology alongside the MyHappyGenes® report, relevant challenge vials for MAO-A assessment include: Serotonin, 5HTP, Tyramine, Histamine, Riboflavin (B2), and Methyl Donors.
Interactions With Other Variants
MAO-A + COMT: When both are slow, the patient has impaired clearance of both serotonin and catecholamines simultaneously. This is one of the most intense mood presentations in functional genetics, high anxiety, high reactivity, poor stress recovery, and significant sleep disruption and often symptoms of obsessive compulsive behaviors. . These cases require careful sequential support; attempting to address both pathways simultaneously can produce unpredictable results. Generally address serotonin and catecholamine clearance before attempting methylation support.
MAO-A + MTHFR: Impaired methylation reduces riboflavin recycling efficiency and limits the methyl groups available for broader neurotransmitter metabolism. In patients with both variants, ( low functioning MAO-A) support for MAO should precede any methylation support to avoid over production of serotonin with low clearance ability.
MAO-A + VDR: Vitamin D upregulates TPH, the enzyme that converts tryptophan to serotonin. In patients with both MAO-A and VDR variants, serotonin production may be compromised at the same time that clearance is dysregulated, creating a complex picture where serotonin levels may be simultaneously high in some compartments and low in others. Attempting to upregulate VDR function without first addressing MAO-A function can result in excess serotonin production and side effects.
A Note on Medication Interactions
MAO-A variants carry some of the most significant medication interaction risks of any gene on the MyHappyGenes® report. Beyond serotonin syndrome risk with serotonergic medications, classic MAO inhibitor drugs — prescribed for depression and Parkinson’s disease, directly inhibit MAO-A activity and can produce severe hypertensive crises when combined with tyramine-rich foods or sympathomimetic medications.
While patients on pharmaceutical MAOIs are a distinct clinical population, the dietary and supplement cautions that apply to that group overlap significantly with what low MAO-A patients need to be aware of. Always conduct a thorough medication review and flag MAO-A status prominently in patient charts.
Working With MyHappyGenes® Reports
MAO-A variants appear in the Mood & Personality Report alongside COMT, MTHFR, VDR, and other mood-regulating genes. Because MAO-A interacts so significantly with the broader methylation cycle and with other neurotransmitter-related variants, the Biochemical Pathways Analysis adds important clinical context — particularly for patients with complex or treatment-resistant mood presentations.
If you’re not yet working with MyHappyGenes® reports in your practice, learn more about our practitioner program here.
